ARMP Stock Overview
A clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Armata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$4.48 |
| 52 Week Low | US$1.98 |
| Beta | 0.80 |
| 11 Month Change | -12.50% |
| 3 Month Change | -16.67% |
| 1 Year Change | 0% |
| 33 Year Change | -61.68% |
| 5 Year Change | -52.05% |
| Change since IPO | -54.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARMP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -21.6% | -3.7% | 0.3% |
| 1Y | 0% | 15.2% | 31.1% |
Return vs Industry: ARMP underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: ARMP underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| ARMP volatility | |
|---|---|
| ARMP Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARMP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARMP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 66 | Deborah Birx | www.armatapharma.com |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Armata Pharmaceuticals, Inc. Fundamentals Summary
| ARMP fundamental statistics | |
|---|---|
| Market cap | US$75.62m |
| Earnings (TTM) | -US$41.36m |
| Revenue (TTM) | US$5.47m |
13.9x
P/S Ratio-1.8x
P/E RatioIs ARMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARMP income statement (TTM) | |
|---|---|
| Revenue | US$5.47m |
| Cost of Revenue | US$33.77m |
| Gross Profit | -US$28.30m |
| Other Expenses | US$13.06m |
| Earnings | -US$41.36m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.14 |
| Gross Margin | -517.71% |
| Net Profit Margin | -756.59% |
| Debt/Equity Ratio | -210.7% |
How did ARMP perform over the long term?
See historical performance and comparison